Sign In
Buy KROS
$11.15
+0.500 (+4.69%)
At Close: Aug 07, 2026
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) co
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company")
NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) co
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why
10:16am, Thursday, 23'rd Jan 2025
KROS stock crashes 81% in three months after dosing with cibotercept was halted in a phase II lung disease study due to adverse pericardial effusion events.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect
10:00am, Thursday, 23'rd Jan 2025
NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company")
KROS ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Keros Therapeutics, Inc. investment
11:00am, Wednesday, 22'nd Jan 2025
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) co
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
10:45am, Wednesday, 22'nd Jan 2025
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). Such investors ar
Keros Therapeutics, Inc. (KROS) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
10:30am, Wednesday, 22'nd Jan 2025
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) co
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company")
Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock?
09:55am, Wednesday, 22'nd Jan 2025
Keros Therapeutics (KROS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price inc
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) co
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
06:15pm, Tuesday, 21'st Jan 2025
NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ: KROS). Such investors are advised
Lost Money on Keros Therapeutics, Inc.(KROS)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
10:30am, Tuesday, 21'st Jan 2025
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) co
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company")
NEW YORK, NY / ACCESS Newswire / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) co
